Testing ways to prevent infection in people with blood cancers
Compares immunoglobulin and antibiotics to prevent infection in adults with blood cancers.
Plain-language title generated from the registry record
Registry title: Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
Key facts
- Where
- Adelaide and Melbourne, AustraliaSee the 3 sites
- Phase
- Phase 2/3
Where in Australia
- Royal Adelaide HospitalAdelaide, AustraliaTaking people
- Austin HospitalMelbourne, AustraliaTaking people
- Northern HealthMelbourne, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Monash University
- Trial code
- NCT07202052
- Record updated
- 7 October 2025
- Original description
This is an adaptive platform study to find out how safe and effective different strategies are in comparison to each other, for preventing infection in patients with blood cancers.Read full original descriptionShow less
A Randomised Platform Trial Evaluating the Role of Interventions to Prevent Infection in Patients With Acquired Hypogammaglobulinemia Secondary to Haematological Malignancies - RATIONAL-PT (Core)
This is an adaptive platform study to find out how safe and effective different strategies are in comparison to each other, for preventing infection in patients with blood cancers.
It is a comparison between Immunoglobulin and antibiotics use.
Inclusion: Aged greater than or equal to 18 years of age; Diagnosis of haematological malignancy, including (CLL) chronic lymphocytic leukemia, (MM) multiple myeloma or (NHL) non-Hodgkin's lymphoma; Eligible to receive or currently receiving Ig (IV or subcutaneous - SCIg) replacement for history of recurrent or severe infection(s) and IgG less than the lower limit of the reference range (excluding paraprotein) OR IgG<4g/L (excluding paraprotein); Life expectancy > 12 months; Able to give informed consent.
Exclusion: Treating team deems enrolment in the study is not in the best interests of the patient.